Adaptive Biotechnologies Corp Stock News

Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Karina Calzadilla - Head of Investor Relations & FP&A Chad Robins - Chief Executive Officer & Co-Founder Kyle Piskel - Chief Financial Officer Susan Bobulsky - Chief Commercial Officer Conference Call Participants Mark Massaro - BTIG David Westenberg - Piper Sandler Y...

SEATTLE, May 01, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2025. “We had a strong start to 2025 with 34% M...

SEATTLE, April 10, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 1, 2025. Company management...

clonoSEQ is now covered to monitor for recurrence in MCL patients who are in treatment-free remission clonoSEQ is now covered to monitor for recurrence in MCL patients who are in treatment-free remission

Enhanced assay granted approval by New York State's Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ is the only DLBCL MRD assay available for clinical use and covered by Medicare SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) --  Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive imm...

Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q4 2024 Results Conference Call February 11, 2025 4:30 PM ET Company Participants Karina Calzadilla - Head of IR & FP&A Chad Robins - CEO and Co-Founder Kyle Piskel - CFO Susan Bobulsky - Chief Commercial Officer Sharon Benzeno - Chief Commercial Officer of Immune Medicine Harlan Robins - Co-Founder & Chief Scientific Officer Conference Call P...

SEATTLE, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2024.

SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences.